After conducting experiments on the impact of BMAL1 on the sensitivity of certain frrst-line cancer treatment drugs, we observed that knocking down BMAL1 increased the sensitivity of AML cells to the drugs venetoclax, dasatinib, and sorafenib. Here, BMAL1 is linked to acute myeloid leukemia.